ReviewWiener medizinische Wochenschrift (1946)2015
Smoking, inflammation and small cell lung cancer: recent developments.
Review in Wiener medizinische Wochenschrift (1946), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Genetic correlation and causal associations between circulating C-reactive protein levels and lung cancer risk.Cancer causes & control : CCC · 2024Article
- Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?Biomolecules · 2024Review
- Smoking induces WEE1 expression to promote docetaxel resistance in esophageal adenocarcinoma.Molecular therapy oncolytics · 2023Article
- Significance of circulating tumor cells in lung cancer: a narrative review.Translational lung cancer research · 2023Review
- Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies.Genes & diseases · 2023Review
- Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells.Oncology research · 2023Article
- Article
- The combined role of PET/CT metabolic parameters and inflammatory markers in detecting extensive disease in small cell lung cancer.Frontiers in oncology · 2022Article
- Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design.Pharmaceutics · 2021Review
- Pulmonary Sensory Receptors.Advances in anatomy, embryology, and cell biology · 2021Article
- Functional Exploration of the Pulmonary NEB ME.Advances in anatomy, embryology, and cell biology · 2021Article
- The mechanism and candidate compounds of aged citrus peel (Food & nutrition research · 2021Article
- MiR-944/CISH mediated inflammation via STAT3 is involved in oral cancer malignance by cigarette smoking.Neoplasia (New York, N.Y.) · 2020Article
- Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A.Oncology letters · 2020Article
- Article
- Circulating tumor cell interactions with macrophages: implications for biology and treatment.Translational lung cancer research · 2017Review
- Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance.Scientific reports · 2017Article
- Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) accounts for 15 % of all lung tumors and represents an invasive neuroendocrine malignancy with poor survival rates. This cancer is highly prevalent in smokers and characterized by inactivation of p53 and retinoblastoma. First in vitro expansion of circulating tumor cells (CTCs) of SCLC patients allowed for investigation of the cell biology of tumor dissemination. In the suggested CTC SCLC model, the primary tumor attracts and educates tumor-promoting and immunosuppressive macrophages which in turn arm CTCs to spread and generate distal lesions. Preexisting inflammatory processes associated with chronic obstructive pulmonary disease (COPD) seem to potentiate the subsequent activity of tumor-associated macrophages (TAM). Activation of signal transducer and activator of transcription 3 (STAT3) and expression of chitinase-3-like 1/YKL-40 in SCLC CTCs seems to be associated with drug resistance. In conclusion, inflammation-associated generation of invasive and chemoresistant CTCs most likely explains the characteristic features of SCLC, namely early dissemination and rapid failure of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.